Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended			3 Months Ended		142 Months Ended
	Aug. 22, 2012	Aug. 07, 2012	May 11, 2012	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 27, 2012	Jun. 30, 2012
Class of Stock [Line Items]
Reverse Stock Split Ratio							10
Issuance of common stock to acquire intellectual property and technology rights		$ 500,000
Issuance of common stock to purchase asset, shares	1,174,536
Purchase price common stock			$ 0.89
Discount to the volume-weighted average price			10.00%
Exercise price			1.19	21.70		21.70
Premium to the volume-weighted average price			20.00%
Warrant exercisable period			5 years
Common stock issued			5,830,202
Warrants issued			2,915,152
Proceeds from issuance of common stock			4,800,000		3,069,000	86,934,000
Warrants outstanding				4,608		4,608
Options outstanding				1,422,389		1,422,389		863,560
Unrecognized compensation expense related to non-vested stock options				537,000		537,000
Expected weighted-average period for recognition of compensation expense				4 years 2 months 12 days
Minimum
Class of Stock [Line Items]
Option Exercise price				$ 0.46		$ 0.46
Maximum
Class of Stock [Line Items]
Potential success-based clinical, regulatory and sales milestone payments		$ 75,200,000
Option Exercise price				$ 6.30		$ 6.30
Rights Offering
Class of Stock [Line Items]
Exercise price				1.19		1.19
Warrants outstanding				2,915,152		2,915,152
Series A warrants
Class of Stock [Line Items]
Exercise price				1.00		1.00
Warrants outstanding				2,460,617		2,460,617
Series A Preferred Stock
Class of Stock [Line Items]
Company designated and issued shares to Isoflavone				1,000
Series A Preferred Stock | Conversion Condition 1
Class of Stock [Line Items]
Each share of Convertible Preferred Stock issued, converted into common stock				4,827
Series A Preferred Stock | Conversion Condition 2
Class of Stock [Line Items]
Each share of Convertible Preferred Stock issued, converted into common stock				9,654